HC Wainwright Predicts Harrow's Q4 Earnings (NASDAQ:HROW)

Key Points

• HC Wainwright raised its Q4 2026 EPS estimate for Harrow to $0.65 from $0.61 and forecast Q3 2027 EPS of $0.32. The current full-year consensus estimate is a loss of $0.02 per share.
• Harrow’s latest quarter beat expectations, with EPS of $0.25 versus $0.19 forecast and revenue of $99.3 million versus $98.59 million expected.
• Analyst views are mixed: six rate Harrow Buy, one Hold and two Sell, leaving a consensus Hold rating and an average price target of $66.20. Shares opened at $29.37, down 3.3%.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at HC Wainwright lifted their Q4 2026 earnings per share estimates for Harrow in a research note issued on Wednesday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.65 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Harrow's current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Harrow's Q3 2027 earnings at $0.32 EPS.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen raised shares of Harrow from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Zacks Research downgraded shares of Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday, November 3rd. BTIG Research reiterated a "buy" rating and set a $63.00 target price on shares of Harrow in a report on Wednesday. Leerink Partners started coverage on Harrow in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 price target on the stock. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Harrow in a research report on Friday, October 16th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Harrow presently has a consensus rating of "Hold" and an average target price of $66.20.

Harrow Stock Down 3.3%

Shares of Harrow stock opened at $29.37 on Thursday. The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.08. The company has a 50-day moving average of $31.15 and a 200 day moving average of $37.67. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -37.65 and a beta of 0.18. Harrow has a 1 year low of $25.76 and a 1 year high of $54.85.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The business had revenue of $99.30 million during the quarter, compared to analyst estimates of $98.59 million.

Insider Buying and Selling at Harrow

In other news, insider Amir Shojaei sold 11,250 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider directly owned 11,250 shares in the company, valued at $450,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Harrow

A number of hedge funds have recently bought and sold shares of the company. KBC Group NV bought a new stake in Harrow during the 1st quarter valued at about $31,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Harrow by 15.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,840 shares of the company's stock worth $215,000 after buying an additional 908 shares in the last quarter. Sterling Capital Management LLC lifted its stake in shares of Harrow by 836.8% in the third quarter. Sterling Capital Management LLC now owns 1,068 shares of the company's stock worth $33,000 after buying an additional 954 shares in the last quarter. First Bancorp Inc ME purchased a new stake in shares of Harrow during the second quarter valued at approximately $64,000. Finally, State of Wyoming purchased a new stake in shares of Harrow during the second quarter valued at approximately $72,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.